Media headlines about Nevro (NYSE:NVRO) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nevro earned a news sentiment score of 0.04 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 45.9590849331357 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Nevro (NYSE NVRO) opened at $86.08 on Tuesday. Nevro has a one year low of $65.00 and a one year high of $97.70. The company has a current ratio of 7.61, a quick ratio of 5.91 and a debt-to-equity ratio of 0.58.
Nevro (NYSE:NVRO) last posted its earnings results on Thursday, February 22nd. The medical equipment provider reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.01). Nevro had a negative return on equity of 15.01% and a negative net margin of 11.22%. The business had revenue of $97.96 million for the quarter, compared to analysts’ expectations of $96.87 million. During the same quarter in the previous year, the firm earned ($0.34) earnings per share. Nevro’s quarterly revenue was up 38.9% compared to the same quarter last year. sell-side analysts anticipate that Nevro will post -0.76 earnings per share for the current year.
A number of equities research analysts have commented on NVRO shares. Zacks Investment Research cut Nevro from a “hold” rating to a “sell” rating in a research note on Wednesday, February 28th. BMO Capital Markets reaffirmed a “buy” rating and set a $100.00 target price on shares of Nevro in a research report on Thursday, December 14th. Finally, ValuEngine lowered Nevro from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $99.25.
In other news, Director Wilfred E. Jaeger sold 14,458 shares of the business’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $83.28, for a total value of $1,204,062.24. Following the completion of the sale, the director now owns 1,518 shares of the company’s stock, valued at approximately $126,419.04. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Wilfred E. Jaeger sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $80.48, for a total value of $804,800.00. Following the transaction, the director now directly owns 1,518 shares of the company’s stock, valued at approximately $122,168.64. The disclosure for this sale can be found here. Insiders sold a total of 234,116 shares of company stock valued at $18,913,822 over the last quarter. Company insiders own 9.10% of the company’s stock.
Nevro Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.